Note 13 - Segment Information

6 Months Ended

Oct. 31, 2016

Notes

Note 13 - Segment Information

NOTE 13 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three and six months ended October 31, 2016 and 2015; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and six months ended October 31, 2016 and 2015 is as follows:

	Three Months Ended October 31,		Six Months Ended October 31,
	2016	2015	2016	2015
Revenues:
Chinese medicine - third party	$         706,115	$            622,793	$      1,380,122	$   1,166,966
Chinese medicine - related party	0	0	0	0
Total Chinese medicine	706,115	622,793	1,380,122	1,166,966
Stevioside - third party	2,791,223	1,677,631	4,991,995	3,036,135
Stevioside - related party	1,948,631	782,398	3,462,369	3,858,054
Total Stevioside	4,739,854	2,460,029	8,454,364	6,894,189
Total segment and consolidated revenues	$      5,445,969	$        3,082,822	$      9,834,486	$   8,061,155
Interest (expense) income:
Chinese medicine	$                    20	$                      67	$                    73	$               136
Stevioside	(88,584)	(86,124)	(169,971)	(164,549)
Total segment and consolidated interest expense	$          (88,564)	$            (86,057)	$        (169,898)	$     (164,413)
Depreciation and amortization:
Chinese medicine	$            72,856	$              60,548	$         148,049	$       152,587
Stevioside	357,468	367,791	700,999	758,021
Total segment and consolidated depreciation and amortization	$         430,324	$            428,339	$         849,048	$       910,608
Income (loss) before income taxes:
Chinese medicine	$        (191,545)	$              15,587	$        (149,896)	$          (8,606)
Stevioside	(368,871)	(306,835	(827,670)	(332,882)
Corporate and other	(350,997)	(108,918	(767,014)	(292,487)
Total consolidated (loss) income before income taxes	$        (911,413)	$          (400,166	$    (1,744,580)	$     (633,975)

	October 31, 2016 (Unaudited)	April 30, 2016
Segment tangible assets:
Chinese medicine	$   1,429,729	$   1,614,531
Stevioside	7,386,482	7,539,546
Corporate and other	0	0
Total consolidated assets	$   8,816,211	$   9,154,077